Capricor presents HOPE-3 OLE data showing deramiocel cut DMD outcome by 76% in patients switched from placebo

Capricor Therapeutics presented 24-month HOPE-3 open-label extension data at the 2026 World Muscle Society Congress showing deramiocel reduced the measured outcome by 76% in Duchenne muscular dystrophy patients who switched to treatment after a year on placebo.

Detected & updated continuously · Source: Nebula